These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36680011)

  • 1. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities.
    Ren A; Tong X; Xu N; Zhang T; Zhou F; Zhu H
    Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.
    Newman H; Teachey DT
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current state of CAR-T therapy for T-cell malignancies.
    Luo L; Zhou X; Zhou L; Liang Z; Yang J; Tu S; Li Y
    Ther Adv Hematol; 2022; 13():20406207221143025. PubMed ID: 36601636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor T cells (CAR-T) for the treatment of T-cell malignancies.
    Cooper ML; DiPersio JF
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101097. PubMed ID: 31779968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cells march into T cell malignancies.
    Tang J; Zhao X
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):13459-13475. PubMed ID: 37468610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-ALL Cells as Tool Cells for CAR T Therapy.
    Ren A; Zhao Y; Zhu H
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
    Polgárová K; Otáhal P; Šálek C; Pytlík R
    Front Oncol; 2022; 12():876758. PubMed ID: 35600381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T Cell Therapy for T-Cell Malignancies.
    Testa U; Chiusolo P; Pelosi E; Castelli G; Leone G
    Mediterr J Hematol Infect Dis; 2024; 16(1):e2024031. PubMed ID: 38468828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
    Alcantara M; Tesio M; June CH; Houot R
    Leukemia; 2018 Nov; 32(11):2307-2315. PubMed ID: 30315238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
    Bouziana S; Bouzianas D
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
    Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of CAR T Cell Therapy for Leukemias.
    Harris K; LaBelle JL; Bishop MR
    Curr Treat Options Oncol; 2021 Jun; 22(7):62. PubMed ID: 34097135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies.
    Xie D; Jin X; Sun R; Zhang M; Wang J; Xiong X; Zhang X; Zhao M
    Technol Cancer Res Treat; 2022; 21():15330338221118413. PubMed ID: 35989682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Cao XY; Li JJ; Lu PH; Liu KY
    Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
    To V; Evtimov VJ; Jenkin G; Pupovac A; Trounson AO; Boyd RL
    Front Immunol; 2022; 13():968395. PubMed ID: 36059451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.
    Caracciolo D; Mancuso A; Polerà N; Froio C; D'Aquino G; Riillo C; Tagliaferri P; Tassone P
    Exp Hematol Oncol; 2023 Jan; 12(1):5. PubMed ID: 36624522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.
    Viardot A; Sala E
    Expert Opin Investig Drugs; 2021 Jul; 30(7):773-784. PubMed ID: 33998346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.
    Jogalekar MP; Rajendran RL; Khan F; Dmello C; Gangadaran P; Ahn BC
    Front Immunol; 2022; 13():925985. PubMed ID: 35936003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.